---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-017994"
form_type: "8-K"
ticker: "BCDA"
cik: "0000925741"
company_name: "BioCardia, Inc."
filed_at: "2026-05-21T12:00:10+00:00"
generated_at: "2026-05-21T12:13:36.011375+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# BioCardia CardiAMP CMI trial: +179 sec exercise tolerance, 82% fewer angina episodes at EuroPCR

## Summary
- Open-label cohort results presented at EuroPCR; no treatment-emergent major adverse cardiac events.
- Exercise tolerance improved by avg 179 seconds, sustained over 2-year follow-up.
- Angina episodes reduced by avg 82% by 6 months after treatment.
- All patients had refractory angina despite guideline-directed medical therapy and prior revascularization.
- Data support continued clinical development of autologous cell therapy for chronic myocardial ischemia.

## SEC filing metadata
- accession: 0001437749-26-017994
- form_type: 8-K
- ticker: BCDA
- cik: 0000925741
- company_name: BioCardia, Inc.
- filed_at: 2026-05-21T12:00:10+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/925741/000143774926017994/0001437749-26-017994-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/925741/000143774926017994/bcda20260520_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-017994
- JSON: https://secwatch.observer/filing/0001437749-26-017994.json
- Plain text: https://secwatch.observer/filing/0001437749-26-017994.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.